Juva Life Files Patent on Family of Non-Cannabinoid Small Molecules Targeting Consumer and Pharma Inflammatory Indications

VANCOUVER, British Columbia, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a California based life sciences company focused on the research, development, and commercialization of Cannabis products today announced the advancement of the JUVA-19 class of compounds into formal development.

JUVA-19 is a non-cannabinoid small molecule isolated from cannabis with previous unappreciated broad spectrum anti-inflammatory properties. Pre-clinical results demonstrate that JUVA-19 inhibits IL1-beta and TNF-alpha in a dose dependent manner. Additionally, the company has identified candidate targets consistent with the regulation of oxidative stress and inflammation.

Juva Life is availing itself of the significant body of literature suggestive of therapeutic benefits of cannabis coupled to modern drug discovery and deep learning tools. The company’s strategy is to develop natural and semi-synthetic compositions alone and in combination for the consumer anti-inflammatory marketplace, and in parallel chemically optimize compositions for select pharmaceutical indications.

The Company’s business strategy is to leverage its unique knowledge of the chemistry and anti-inflammatory mode of action of non-cannabinoid compositions contained within cannabis to develop safe and effective therapeutics. The company intends to develop products through pre-clinical in vivo validation studies, and partner with leading pharma and consumer companies seeking anti-inflammatory bioactives for their product pipelines. On October 6, 2021, the company filed a provisional patent with the United States Patent and Trademark Office (USPTO) on method of use of the natural compositions, and composition of matter claims on non-naturally occurring semi-synthetic and synthetic analogs.

Company CEO, Doug Chloupek states, “We are pleased of the progress of our internal research and development activities.” Mr. Chloupek continues, “Our next steps are to build upon our initial findings by profiling the Juva-019 class of compounds in gold standard in-vivo models of inflammation, paving the way for evidenced-based product development.”

In separate news, the Company is pleased to announce the appointment of Dr. Peter Beitsch to its Board of Directors, effective immediately.

Dr. Beitsch has held numerous positions in national surgical societies including the American Society of Breast Surgeons where he served as President of the Society from 2013-14, first Chairman of the Membership Committee 2001-4, Program Director for the 2005 Annual Meeting in Los Angeles, Board of Directors Member from 2006-9 and 2012-15. He has served on the Executive Committee of the Society of Surgical Oncology 2008-2010, General Surgical Oncology Committee of the American Board of Surgery and was a National Ultrasound Faculty for the American College of Surgeons.

Dr. Beitsch has presented internationally and is actively involved in breast cancer and melanoma research. He has authored major articles in peer-reviewed medical journals including the New England Journal of Medicine, the Journal of the American Medical Association, the Proceedings of the National Academy of Science, Journal of Clinical Oncology, and the Annals of Surgical Oncology.

Company CEO, Doug Chloupek states, “I am very pleased to welcome Dr. Beitsch to our Board today. The timing is excellent as we ramp our investigative endeavors into new and exciting compounds. Dr. Beitsch has provided excellent advice, and insights through his previous role as an adviser to the Company and we are looking forward to his expanded role.”

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder
Juva Life Inc.
[email protected]

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)
Juva Life is employing state-of-the-art science to discover, develop and commercialize safe and effective Cannabis products. The Company is successfully executing against its 2018 roadmap, initially starting with standardization of cultivation, extraction, and formulation to offer consumers reproducible benefits. Juva is building upon these natural product process chemistry skills, to now include discovery pharmacology. The Company will leverage revenue derived from its retail operations to advance Juva-019 and other potentially valuable non-cannabinoid bioactives for consumer and pharma products applications. Juva is working to bring the Cannabis market face to face with the sector’s next generation investment grade business model. Find out more at: https://juvalife.com/. 

For further information, please contact:
Juva Life Investor Relations
Tel: +1 833-333-5882 (JUVA)
Email: [email protected]

Forward Looking Statement
This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2020 under the heading “Risks and Uncertainties”. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.